Roic.ailogo
Powered by AI
US stock · Healthcare sector · Biotechnology
Company Logo

BioCryst Pharmaceuticals, Inc.

BCRXNASDAQ

8.01

USD
-0.09
(-1.11%)
Market Closed
-6.44P/E
-14Forward P/E
-0.30P/E to S&P500
1.525BMarket CAP
- -Div Yield
SummaryFinancialsTranscriptsMonitoringClassic View
Upcoming Earnings
3 May-8 May
Shares Short
2/28/23
29.48M
Short % of Float
17.52%
Short % of Shares Outs.
15.64%
% Held by Insiders
1.03%
% Held by Institutions
85.55%
Beta
2.03
PEG Ratio
-0.18
52w. high/low
18.00/7.61
Avg. Daily Volume
3.08M
Return %
Stock
S&P 500
1 year
(47.50)
(9.05)
3 years
301.45
50.26
5 years
55.33
38.50
Scale: |
High
Low
6.53
0.85
13.47
1.15
8.37
4.43
5.43
2.28
5.95
1.08
7.84
1.12
14.62
7.29
16.83
7.85
10.24
1.63
9.25
3.95
9.71
4.25
9.95
1.38
8.99
1.58
18.48
7.27
19.99
7.61
12.07
7.82
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Revenue per share
2.17
1.49
1.92
1.40
0.44
0.53
0.31
0.20
0.66
0.36
0.30
0.20
0.42
0.11
0.88
1.51
Earnings per share
(0.89)
(0.65)
(0.35)
(0.76)
(1.26)
(0.79)
(0.55)
(0.68)
(0.59)
(0.75)
(0.78)
(0.98)
(0.94)
(1.09)
(1.03)
(1.38)
FCF per share
(0.76)
(0.58)
(0.43)
(0.65)
(0.72)
(0.76)
(0.48)
(0.58)
(0.25)
(0.80)
(0.49)
(0.90)
(0.78)
(0.82)
(0.81)
(0.91)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
0.03
0.02
0.01
0.00
0.00
0.00
0.00
0.07
0.07
0.00
0.00
0.00
0.00
0.01
0.01
Book Value per sh.
1.98
1.22
2.22
1.47
0.33
(0.01)
(0.02)
1.13
0.65
0.02
0.99
0.48
0.33
(0.12)
(0.60)
(8.12)
Comm.Shares outs.
33
38
39
45
45
49
55
67
73
74
84
103
116
167
179
179
Avg. annual P/E ratio
(9.9)
(4.8)
(17.4)
(8.1)
(2.8)
(4.5)
(6.8)
(16.3)
(19.2)
(5.9)
(7.4)
(6.3)
(5.3)
(3.8)
(13.0)
(9.5)
P/E to S&P500
(0.6)
(0.2)
(0.2)
(0.4)
(0.2)
(0.3)
(0.4)
(0.9)
(1.0)
(0.3)
(0.3)
(0.3)
(0.2)
(0.1)
(0.4)
(0.4)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
71
57
75
62
20
26
17
14
48
26
25
21
49
18
157
271
Operating margin
(45.3)%
(48.0)%
(18.4)%
(55.1)%
(252.4)%
(128.9)%
(177.2)%
(336.4)%
(81.7)%
(184.4)%
(227.9)%
(456.2)%
(203.7)%
(981.1)%
(113.1)%
(54.8)%
Depreciation (m)
1
2
2
2
1
1
0
0
0
0
1
1
1
1
1
(0)
Net profit (m)
(29)
(25)
(13)
(34)
(57)
(39)
(30)
(45)
(43)
(55)
(66)
(101)
(109)
(183)
(184)
(247)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(1.2)%
(1.1)%
Net profit margin
(40.8)%
(43.7)%
(18.0)%
(54.3)%
(289.9)%
(148.6)%
(173.7)%
(332.1)%
(89.1)%
(209.3)%
(261.2)%
(490.3)%
(223.0)%
(1,026.4)%
(117.1)%
(91.2)%
Working capital (m)
64
58
74
60
27
25
27
32
2
13
51
45
72
218
462
411
Long-term debt (m)
- -
- -
- -
- -
30
30
30
- -
- -
23
17
25
41
244
591
6
Equity (m)
65
46
86
66
15
(0)
(1)
76
48
2
84
49
38
(19)
(107)
(1,455)
ROIC
- -
- -
- -
- -
(95.1)%
(85.6)%
(75.4)%
(50.8)%
(62.9)%
(137.1)%
(55.3)%
(119.0)%
(116.9)%
(73.5)%
(25.6)%
20.5%
Return on capital
(20.4)%
(29.2)%
(9.5)%
(30.9)%
(64.7)%
(59.9)%
(51.8)%
(29.4)%
(30.4)%
(54.2)%
(32.1)%
(62.7)%
(55.3)%
(50.3)%
(20.8)%
23.8%
Return on equity
(44.8)%
(53.3)%
(15.6)%
(51.7)%
(384.6)%
8,608.1%
2,673.9%
(59.7)%
(90.1)%
(3,494.6)%
(78.5)%
(205.7)%
(284.7)%
949.1%
172.0%
17.0%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
27 Feb · 2023 | Q4
All numbers in millions
Total liabilities
$ 845
Total assets
$ 550
Long-term debt
$ 6
Cash and equiv.
$ 305
Goodwill
$ - -
Retained earnings
$ (1,455)
Common stock
187
Enterprise Value
$ 1,226
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
300
508
424
Receivables
9
29
51
Inventory
7
16
28
Other
8
246
47
Current assets
324
566
517
Acc. Payable
19
28
14
Debt due
31
2
- -
Other
56
74
91
Current liabilities
106
104
106
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
72.31%
231.91%
121.44%
Cash flow
12.91%
16.95%
41.91%
Earnings
34.26%
27.59%
28.56%
Dividends
- -
- -
- -
Book value
1,259.64%
385.60%
(26.79)%
Insider Trading
Type
Shares
Date
Milano Vincent
Award
635
02/28/23
Ingram Robert Alexander
Award
2,259
02/28/23
Levin Alan G
Award
1,271
02/28/23
Heggie Theresa
Award
635
02/28/23
Stonehouse Jon P
Exempt
100,000
02/01/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
5
3
6
4
18
2021
19
50
41
47
157
2022
50
66
76
80
271
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.22)
(0.23)
(0.28)
(0.36)
(1.09)
2021
(0.36)
(0.24)
(0.33)
(0.10)
(1.03)
2022
(0.41)
(0.33)
(0.24)
(0.40)
(1.38)
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Jon P. Stonehouse
Full-time employees:
358
City:
Durham
Address:
4505 Emperor Boulevard
IPO:
Mar 4, 1994
CIK:
0000882796
Website:
biocryst.com
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Recent News